Acute Leukemia in Adolescents and Young Adults

Seminars in Oncology

Volumn 36, Issue 3, 2009, Pages 213-226

  Advani, Anjali S ^a   Hunger, Stephen P ^b   Burnett, Alan K ^c  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ASPARAGINASE; CORTICOSTEROID; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; NELARABINE; PREDNISONE; RETINOIC ACID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AVASCULAR NECROSIS; BLEEDING; BLOOD TOXICITY; BONE NECROSIS; CANCER INCIDENCE; CANCER SURVIVAL; DOSAGE SCHEDULE COMPARISON; EVENT FREE SURVIVAL; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; PANCREATITIS; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PUBERTY; RISK FACTOR; SEPSIS; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 65549167216     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.03.007     Document Type: Article

References (66)

1. Bleyer A., Montello M., and Budd T. Young adults with leukemia in the United States: lack of clinical trial participation and mortality reduction during the last decade [abstract]. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22 Suppl 14 (2004) 6623
2. Larson S., and Stock W. Progress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol 14 (2008) 400-407
3. Usvasalo A., Raty R., Knuutila S., Vettenranta K., Harila-Saari A., Jantunen E., et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica 93 (2008) 1161-1168
4. DeAngelo D.J. The treatment of adolescents and young adults with acute lymphoblastic leukaemia. Am Soc Hematol Educ Book (2005) 123-130
5. Secker-Walker L.M., Craig J.M., Hawkins J.M., and Hoffbrand A.V. Philadelphia chromosome positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 5 (1991) 196-199
6. Aguiar R.C., Sohal J., van Rhee F., Carapeti M., Franklin I.M., Goldstone A.H., et al. TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. MRC Adult Leukaemia Working Party. Br J Haematol 95 (1996) 673-677
7. Borkhardt A., Cazzaniga G., Viehmann S., Valsecchi M.G., Ludwig W.D., Burci L., et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologica Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 90 (1997) 571-576
8. Jeha S. Who should be treating adolescents and young adults with acute lymphoblastic leukaemia?. Eur J Cancer 39 (2003) 2579-2583
9. Whitehead V.M., Vuchich M.J., Lauer S.J., Mahoney D., Carroll A.J., Shuster J.J., et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukaemia: a Pediatric Oncology Group study. Blood 80 (1992) 1316-1323
10. Nachman J., Masera G., and Bleyer A. Acute Lymphoblastic leukemia. In: Bleyer W.A., and Barr R.E. (Eds). Cancer in adolescents and young adults (2007), Springer, Heidelberg 83-98
11. Ferrando A.A., Neuberg D.S., Staunton J., Loh M.L., Huard C., Raimondi S.C., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1 (2002) 75-87
12. Weng A.P., Ferrando A.A., Lee W., Morris J.P., Silverman L.B., Sanchez-Irizarry C., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306 (2004) 269-271
13. Nachman J. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol 130 (2005) 166-173
14. Kaspers G.J., Veerman A.J., Pieters R., Van Zantwijk C.H., Smets L.A., Van Wering E.R., et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90 (1997) 2723-2729
15. Roman-Gomez J., Jimenez-Velasco A., Castillejo J.A., Agirre X., Barrios M., Navarro G., et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104 (2004) 2492-2496
16. Stock W., La M., Sanford B., Bloomfield C.D., Vardiman J.W., Gaynon P., et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols?. A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 112 (2008) 1646-1654
17. Boissel N., Auclerc M.F., and Lheritier V. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults?. Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21 (2003) 774-780
18. de Bont J.M., Holt B., Dekker A.W., van der Does-van den B., Sonneveld P., and Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs. adult protocols in the Netherlands. Leukemia 18 (2004) 2032-2035
19. Nachman J., Sather H.N., Buckley J.D., Gaynon P.S., Steinherz P.G., Tubergen D.G., et al. Young adults 16-21 years of age at diagnosis entered on Children's Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer 71 (1993) 3377-3385
20. Ribera J.M., Oriol A., Sanz M.A., Tormo M., Fernandez-Abellan P., del Potro E., et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Program Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 26 (2008) 1843-1849
21. DeAngelo D., Dahlberg S., and Silverman L.B. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukaemia [abstract]. Blood 110 (2007) 587
22. Huget F., Pigneux A., Thomas X.P., Chevallier A., Buzyn Y., Chalandon E., et al. For the Group for Research on Adult ALL (GRAALL). Outcome of a pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL): final results of the GRAALL-2003 study [abstract]. J Clin Oncol ASCO Annual Meeting Proceedings 26 (2008) 7005
23. Goldstone A.H., Richards S.M., Fielding A.K., and Rowe J.M. Chemotherapy or allografting for young adults with high-risk ALL? Response. Blood 111 (2008) 5755
24. Rubnitz J.E., Lensing S., Zhou Y., Sandlund J.T., Razzouk B.I., Ribeiro R.C., et al. Death during induction therapy and first remission of acute leukemia in childhood. Cancer 101 (2004) 1677-1684
25. Mattano L.A., Sather H.N., Trigg M.E., and Nachman J.B. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 18 (2000) 3262-3272
26. Barry E., DeAngelo D.J., Neuberg D., Stevenson K., Loh M.L., Asselin B.L., et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium protocols. J Clin Oncol 25 (2007) 813-819
27. Kern W., Haferlach T., Schoch C., Loffler H., Gassmann W., Heinecke A., et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCF) 1992 trial. Blood 101 (2002) 64-70
28. Wheatley K., Burnett A.K., Goldstone A.H., Gray R.G., Hann I.M., Harrison C.J., et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107 (1999) 69-79
29. Slovak M., Kopecky K., Cassileth P.A., Harrington D.H., Theil K., Mohamed A., et al. Karyotypic analysis predicts outcome of pre-remission and post-remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96 (2000) 4075-4083
30. Grimwade D., Walker H., Oliver F., Wheatley K., Harrision C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92 (1998) 2322-2333
31. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C., et al. The predictive value of hierarchical cytogenetic classification in older adults with AML: analysis of 1,065 patients entered into the MRC AML11 Trial. Blood 98 (2001) 1312-1320
32. Burnett A.K., Goldstone A.H., and Wheatley K. Core binding factor leukaemias are a discrete group: experience from MRC AML 10, 11 and 12 trials. Br J Haematol 105 (1999) 67
33. Burnett A.K., Hills R.K., Wheatley K., Goldstone A.H., Prentice A.G., and Milligan D. A sensitive risk score for directing treatment in younger patients with AML. Blood 108 (2006) 10a
34. Bowen D.T., Frew M.E., Hills R., Gale R.E., Wheatley K., Groves M.J., et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 106 (2005) 2113-2119
35. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S., Belton A.A., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukaemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
36. Levis, and Small D. ITD does matter in leukemia?. Leukemia 17 (2003) 1738-1752
37. Frohling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study group Ulm. Blood 100 (2002) 4372-4380
38. Mead A.J., Linch D.C., Hills R.K., Wheatley K., Burnett A.K., and Gale R.E. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110 (2007) 1262-1270
39. Dohner K., Schlenk R.F., Habdank M., Scholl C., Rucker F.G., Corbacioglu A., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106 (2005) 3740-3746
40. Gale R.E., Green C., Allen C., Mead A.J., Burnett A.K., Hills R.K., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111 (2008) 2776-2784
41. Frohling S., Schlenk R.F., and Stolze I. CEBPα mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22 (2004) 624-633
42. Preudhomme C., Sagot C., Boissel N., Cayuela J.M., Tigaud I., de Botton S., et al. Favorable prognostic significance of CEBPα mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukaemia French Association (ALFA). Blood 100 (2002) 2717-2723
43. Cairoli R., Beghini A., Grillo G., bu-Duhier F.M., Geertsma-Kleinekoort W.M., Wilson G.A., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107 (2006) 3463-3468
44. Care R.S., Valk P.J., Goodeve A.C., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 121 (2003) 775-777
45. Paschka P., Marcucci G., Ruppert A.S., Mrozek K., Chen H., Kittles R.A., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol 24 (2006) 3904-3911
46. Virappane P., Gale R., Hills R., Kakkas I., Summers K., Stevens J., et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia. J Clin Oncol 26 (2008) 5429-5435
47. Barjesteh van Waalwijk S., van Doorn-Khosrovani S., Erpelinck C., van Putten W.L., Valk P.J., van der Poel-van de Luytgaarde, Hack R., et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101 (2003) 837-845
48. Venditti A., Buccisano F., Del Poeta C., Maurillo L., Tamburini A., Cox C., et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96 (2000) 3948-3952
49. San Miguel J.F., Martinez A., Macedo A., Vidriates M.B., Lopez-Berges C., Gonzalez M., et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 90 (1997) 2465-2470
50. Sievers E.L., Lange B.J., Alonzo T.A., Gerhing R.B., and Smith Haferlach I.D. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104 (2004) 3078-3085
51. Kern W., Voskova D., Schoch C., Hiddemann W., Schnittger S., and Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104 (2004) 3078-3085
52. Coustan-Smith E., Ribeiro R.C., Rubnitz J.E., Razzouk B.I., Pui C.H., Pounds S., et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 123 (2003) 243-252
53. Feller N., van der Pol M.A., van Stijn A., Weijers G.W., Westra A.H., Evertse B.W., et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18 (2004) 1380-1390
54. Langebrake C., Creutzig U., Dworzak M., Hrusak O., Mejstrikova E., Griesinger F., et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM study group. J Clin Oncol 24 (2006) 3686-3692
55. Freeman S.D., Jovanovic J.V., and Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 35 (2008) 388-400
56. Grimwade D.J., Jovanovic J., Hills R., Nugent E., Patel Y., Flora R.D., et al. Evaluation of prospective detection of PML-RARA and RARA-PML fusion transcripts by real-time quantitative PCR (RQ-PCR) to direct pre-emptive therapy with arsenic trioxide (ATO) in acute promyelocytic leukemia (APL) patients treated in the UK MRC AML15 trial. Blood 110 (2007) 166A-167A
57. Hann I.M., Stevens R.F., Goldstone A.H., Rees J.K., Wheatley K., Gray R.G., et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukaemia. Results of the Medical Research Council's 10th AML Trial (MRC AML 10). Blood 89 (1997) 2311-2318
58. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the international Working Group for diagnosis, standardization of response criteria treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21 (2003) 4642-4649
59. Burnett A.K., Kell W.J., Goldstone A.H., Milligan D., Hunter A., Prentice A.G., et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. Blood 108 (2006) 8A
60. Arceci R.J., Burnett A.K., Estey E., Hills R., and Woods W.G. Acute myelogenous leukaemia in adolescent and young adults: what is the optimal therapy?. ASCO Educational Book (2006) 533-541
61. Tallman M.S., Nabhan C., Feusner J.H., and Rowe J.M. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99 (2002) 759-767
62. Sanz M., Martín G., González M., Leon A., Rayon C., Rivas C., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103 (2004) 1237-1243
63. Sanz M.A., Tallman M.S., and Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 105 (2005) 3019-3025
64. Ghavamzadeh A., Alimoghaddam K., Ghaffari S.H., Rostami S., Jahani M., Hosseini R., et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 17; (2006) 131-134
65. Estey E., Garcia-Manero G., Ferrajoli A., Faderl S., Verstovsek S., Jones D., et al. Use of all-trans retinoic acid + arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107 (2006) 3469-3473
66. Sanz M.A., Grimwade D., Tallman M.S., Lowenberg B., Fenaux P., Estey E.H., et al. Guidelines on the management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 113 (2009) 1875-1891